Article
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.
Cell reports - 11 Oct 2022
Wang Lin, Wang Dan, Sonzogni Olmo, Ke Shizhong, Wang Qi, Thavamani Abhishek, Batalini Felipe, Stopka Sylwia A, Regan Michael S, Vandal Steven, Tian Shengya, Pinto Jocelin, Cyr Andrew M, Bret-Mounet Vanessa C, Baquer Gerard, Eikesdal Hans P, Yuan Min, Asara John M, Heng Yujing J, Bai Peter, Agar Nathalie Y R, Wulf Gerburg M
Abstract excerpt
Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), including tumor-associated macrophages (TAMs). As TAMs can promote or inhibit tumor growth, we set out to examine the effects of PARP inhibition on TAMs in BRCA1-related breast cancer (BC). The PARPi olaparib causes reprogramming of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.